MicroVision, Inc.
26.7.2021 22:11:48 CEST | ACCESS Newswire | Press release
REDMOND, WA / ACCESSWIRE / July 26, 2021 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS based solid state automotive lidar and micro-display technology for augmented reality, today announced the hiring of Dr. Thomas Luce as Vice President of Business Development, focused on European and Middle East markets, as well as plans to open a new office in Germany to help promote the Company's automotive lidar technology and sensor to OEMs and Tier 1 suppliers.
"As interest in our lidar technology grows, our presence in Germany allows us to work more closely with potential partners and customers," said Sumit Sharma, MicroVision's Chief Executive Officer. "I am thrilled that Dr. Luce will lead our business development efforts in Europe and the Middle East. Based on the data we have shared to date with OEMs and mobility-as-a-service companies, a local presence will help us work closely to ensure that our LRL sensor meets or exceeds target OEM and Tier 1 expectations. Initial feedback from potential partners and customers has been positive. I am happy about our progress so far. With COVID restrictions lifting and staff starting to return to the office, we look forward to our team moving to track testing of our sensor."
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Joining MicroVision on September 1, 2021, Dr. Luce is a seasoned executive with more than 25 years of experience in Automotive Lighting and Optics. He held various leadership roles at Philips Automotive Lighting, Schefenacker, Valeo and Eschenbach Optik. Most recently, he served as CEO for Optoflux GmbH, where he grew the company into a global automotive and optics company, adding LED and lidar optics to the company portfolio. With an extensive career in the automotive area, he has deep insight into the automotive sensor and lighting community. He studied Physics and Chemistry at Heidelberg and Berlin University, as well as Business Administration at Hagen. He earned his PhD with great honor in nonlinear optics at Free University Berlin.
"I am thrilled by the opportunity to join the MicroVision team and to develop the MicroVision business in Europe," said Dr. Luce. "I believe that especially the premium car manufacturers are now strongly pushing for autonomous driving, and I am convinced that the lidar solution MicroVision could provide to its Automotive customers will be an enabler for autonomy and safety for the future. I see a huge potential to capture a significant share of the lidar sensor market and to create value for MicroVision's shareholders."
About MicroVision
MicroVision is a pioneering company in MEMS based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology to provide solutions for automotive lidar sensors, augmented reality micro-display engines, interactive display modules and consumer lidar modules.
For more information, visit the Company's website at www.microvision.com, on Facebook at www.facebook.com/microvisioninc or follow MicroVision on Twitter at @MicroVision.
MicroVision is a trademark of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.
Forward-Looking Statements
Certain statements contained in this release, including those related to the Company's opening of a new office, engaging with potential partners and customers, market opportunity, product features, solutions and applications and building value for shareholders are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk that the Company may not succeed in finding licensing or other strategic solutions, including a potential sale of the Company, with acceptable timing, benefits or costs; its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements, including from the impact of COVID-19 (coronavirus); its ability to identify parties interested in paying any amounts or amounts that the Company deems desirable for the purchase or license of intellectual property assets; its or its customers' failure to perform under open purchase orders; its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain additional contract awards and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.
Investor Relations Contact
David H. Allen
Darrow Associates, Inc.
408.427.4463
dallen@darrowir.com
SOURCE: MicroVision, Inc.
View source version on accesswire.com:
https://www.accesswire.com/657076/MicroVision-Hires-Dr-Thomas-Luce-to-Lead-EMEA-Business-Development-and-Announces-Opening-of-Germany-Office
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Medical Component Specialists to Support Advanced Catheter Innovation at The Catheter R&D Masterclass in Ireland4.5.2026 21:30:00 CEST | Press release
BELLINGHAM, MA / ACCESS Newswire / May 4, 2026 / Medical Component Specialists (MCS), a premier manufacturer of precision medical components, today announced its participation as a supporting organization at The Catheter R&D Masterclass. Hosted by Eyedea Medtech, the highly anticipated event will take place May 28-29, 2026, at the Prototyping and Education Facility in Westport, Mayo, Ireland. The Catheter Systems Lab is an exclusive, dual-purpose educational program designed for senior engineers with over a decade of experience in catheter-based medical device development. Over the course of two days, industry leaders will engage in a deep exploration of catheter design, materials science, structural reinforcement, and end-to-end manufacturing pathways. As a supporting organization, Medical Component Specialists will play a vital role in the event's structured insight and data capture initiatives. The masterclass will facilitate meaningful technical dialogue, allowing MCS to gain direc
Pacific Avenue Capital Partners Enters into Exclusive Negotiations to Acquire ESE World, Amcor's European Waste Container Business4.5.2026 09:30:00 CEST | Press release
LOS ANGELES, CA AND PARIS, FR / ACCESS Newswire / May 4, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, announced today that an affiliate of Pacific Avenue has entered into exclusive negotiations to acquire ESE World (the "Company" or "ESE") from Amcor, one of the world's leading global packaging companies. ESE is the foremost European manufacturer of both plastic and steel waste containers and a provider of associated waste management services. The Company generates approximately €300m of revenues and serves customers across the world from its three manufacturing facilities in Germany (Neuruppin and Olpe) and France (Crissey). Under Pacific Avenue's stewardship, ESE will focus its efforts on meeting the needs of its customers and executing several growth initiatives tied to operational improvement, geographic expansion, and strategic add-on acquisitions. Pacifi
Securitas Acquires CamVision to Expand Packaged and Advanced Security Solutions in Denmark4.5.2026 09:00:00 CEST | Press release
STOCKHOLM, SE / ACCESS Newswire / May 4, 2026 / Securitas has acquired CamVision, a Danish technology driven security specialist with a strong position in retail loss prevention and electronic security solutions. The acquisition strengthens Securitas' ability to deliver reliable and scalable security solutions for micro and small singlesite businesses as well as larger, multisite clients across Denmark. For micro and small businesses, the acquisition enhances Securitas' offering of standardized, packaged security solutions that combine proven technology with dependable service delivery. For larger and multisite clients, it further strengthens Securitas' capability to deliver advanced, technology led security systems designed for complex operational environments. "With the acquisition of CamVision, we strengthen our offering for micro and small business clients, particularly within retail. By combining proven security technology with standardized service delivery, we can offer simpler,
Formerra Appoints Matt Borowiec as Chief Commercial Officer1.5.2026 15:00:00 CEST | Press release
CLEVELAND, OH / ACCESS Newswire / May 1, 2026 / Formerra, a leading distributor of performance materials, today announced the appointment of Matt Borowiec as Chief Commercial Officer (CCO). Borowiec will lead the company's commercial organization to support continued growth and global expansion while strengthening sales execution and customer success. Borowiec is a seasoned executive with over 25 years' experience in operations, commercial and P&L roles across resin manufacturing, specialty compounding, and distribution, including leadership roles at GE Plastics, PolyOne (now Avient), Transcendia, Celanese, and Kinsley Group. With this background, he is well positioned to lead Formerra's commercial strategy at this important time in the company's evolution. "Matt brings a unique combination of producer‑side and distribution experience that positions him well to strengthen alignment between our suppliers, customers, and commercial teams," said Tom Kelly, Chief Executive Officer at Forme
Global Experts call for Paradigm Shift in Medicine, Health and Education to Save Lives and Fight Escalating Health Crisis1.5.2026 14:48:00 CEST | Press release
INNSBRUCK, AUSTRIA / ACCESS Newswire / May 1, 2026 / A global consortium of 64 experts (72 entities, 5 continents) unveiled two coordinated consensus plus policy brief reports, outlining a science‑driven roadmap to confront escalating health crises and to tackle the growing burden of noncommunicable diseases (NCDs-including cardiovascular diseases, cancer, diabetes, etc.: 75% of global deaths; 82% in low-/middle income countries; 90% of all death in European region). The centerpiece is HEAL-Healthy Eating & Active Living, ideally whole‑food plant‑predominant/vegetarian-vegan diets & daily exercise outdoors/active mobility-as the minimum, first‑line standard in health and care. The authors urge immediate action on Prevention-over-Treatment and reforming education and human‑relevant science (drug failure rate from animal studies is 90-95%, and as high as 99.6% for Alzheimer disease), with a rapid shift from disease‑centered reaction to person‑centered, lifestyle‑first cure and care. Figu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom